Search filters

Filters
Clear All

Phase

  • 3
  • 7
  • 3
  • 1
  • 14
  • 11
  • 14

Found 14 Solid Tumors trials

A listing of Solid Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

18 years or above
All genders
Phase 1
Interventional
APT-008 is an open-label, Phase I/Ib, dose escalation and expansion cohort study to evaluate the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and preliminary efficacy of EOS301984 as monotherapy and in combination with other anticancer therapies in participants with advanced solid tumors.
99 years or below
All genders
Phase 2
Indocyanine Green (ICG) is an FDA approved, water-soluble tricarbocyanine dye routinely used in clinical settings for measuring cardiac output, liver function, and retinal angiography and has been in use for over 50 years. Patient diagnosed with solid tumor cancers have a high rate of recurrence when surgery is a treatment. …
99 years or below
All genders
Phase 1
This is a Phase 1 study that will evaluate the effectiveness of TPST-1120. Subjects may receive TPST-1120 alone or in combination with nivolumab. Subjects eligible to participate are those with advanced solid tumors.
99 years or below
All genders
Phase 1
Multi-center, open-label, first in human (FIH) Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CARTTnMUC1 cells). …
99 years or below
All genders
Phase 1
The purpose of this Study is to test the safety and tolerability of the INCB086550 and to find out what effects, if any, the INCB086550 has on people and their cancer. The INCB086550 has been tested in animals but not yet in people. This Study will test different doses of …
 A Phase II  Open Label  Multi-Dose Study of 89Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Metastatic Solid Tumors.
18 years - 99 years
All genders
Phase 2
The research study is being conducted to test a new investigational imaging agent called 89Zr-Df-IAB22M2C with positron emission tomography/computed tomography (PET/CT) scans on subjects with cancer who plan to be treated as part of the clinical care. The imaging agent could help the doctor see where your CD8+ T cells …
1 - 10 of 14